INV 103

Drug Profile

INV 103

Alternative Names: ala-chaperonin-10; Ala-Cpn10; Chaperonin 10; Cpn 10; Heat shock protein 10 - Invion; HSP-10 - Invion; INV103; Recombinant Cpn 10; XToll

Latest Information Update: 13 Oct 2015

Price : $50

At a glance

  • Originator CBio
  • Developer CBio; Invion
  • Class Anti-inflammatories; Antirheumatics; Chaperonins
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Autoimmune disorders

Highest Development Phases

  • Phase I/II Systemic lupus erythematosus
  • No development reported Multiple sclerosis; Plaque psoriasis; Rheumatoid arthritis
  • Discontinued Ulcerative colitis

Most Recent Events

  • 14 Nov 2014 HSP 10 is available for licensing as of 14 Nov 2014. http://inviongroup.com
  • 01 Jul 2013 No development reported - Phase-II for Plaque psoriasis in Australia (IV)
  • 01 Jul 2013 No development reported - Phase-II for Multiple sclerosis in Australia (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top